Polymorphic forms of sertraline hydrochloride
US6872853B1 · kind B1 · utility
11Cited by
9References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 23, 2000 |
| Grant date | Mar 29, 2005 |
| Priority date | — |
| Expiry date | Feb 10, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2602/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A cystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug. Furthermore, different crystalline forms of sertraline hydrochloride alcohol solvates, crystalline forms of sertraline hydrochloride hydrates, referred to hereinafter as polymorphic form CSC1, a process for the preparation of the amorphous form of sertraline hydrochloride, and different processes for the preparation of polymorphic forms I, II, V, and T1 are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.